Literature DB >> 16615107

Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.

Brenda B J Hermsen1, Paul J van Diest, Johannes Berkhof, Fred H Menko, Johan J P Gille, Jurgen M J Piek, Sybren Meijer, Henri A H Winters, Peter Kenemans, Silvia von Mensdorff-Pouilly, René H M Verheijen.   

Abstract

To analyse the prevalence of (pre) malignant lesions occurring in breast and adnexal tissue at prophylactic surgery in women at hereditary high risk of breast and/or ovarian cancers. Tissue was obtained from 85 women who underwent prophylactic bilateral salpingo-oophorectomy (pBSO) and from 59 women who underwent prophylactic mastectomy (pM). Control tissue samples were obtained from women undergoing breast reduction surgery (N = 99) or adnexal surgery for benign reasons (N = 72). In women with a BRCA1/2 mutation, the prevalence of a (pre) malignant adnexal lesion was 50% (95% CI 26-74) if older than 40 years and 14% (95% CI 0-58) if younger. The prevalences of (pre) malignant breast lesions in women older than 40 years, with and without a BRCA1/2 mutation, were 0% (95% CI 0-16) and 47% (95% CI 21-73), respectively. No association was found between (pre) malignant lesions in breast and adnexal tissue occurring in 28 women who underwent surgery on both organs (R = 0.155, p = 0.432), but the prevalence of lesions was significantly higher in adnexal tissue than in the breast (p = 0.023). Compared to controls, women at hereditary high risk had a higher chance of (pre) malignant lesions in the breast and an even higher chance of such lesions in the adnexal tissue. There was no indication for concomitant presence of such lesions in both organs at the time of prophylactic surgery. The high frequency of (pre) malignant lesions in the adnexal tissue stresses further the importance of pBSO from the age of 40 onwards in women at hereditary high risk.

Entities:  

Mesh:

Year:  2006        PMID: 16615107     DOI: 10.1002/ijc.21988

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

Authors:  Mark H Greene; Phuong L Mai; Peter E Schwartz
Journal:  Am J Obstet Gynecol       Date:  2010-07-08       Impact factor: 8.661

2.  Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.

Authors:  Susan M Domchek; Tara M Friebel; Judy E Garber; Claudine Isaacs; Ellen Matloff; Rosalind Eeles; D Gareth Evans; Wendy Rubinstein; Christian F Singer; Stephen Rubin; Henry T Lynch; Mary B Daly; Jeffrey Weitzel; Patricia A Ganz; Gabriella Pichert; Olufunmilayo I Olopade; Gail Tomlinson; Nadine Tung; Joanne L Blum; Fergus Couch; Timothy R Rebbeck
Journal:  Breast Cancer Res Treat       Date:  2010-02-24       Impact factor: 4.872

3.  Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.

Authors:  Russell Vang; Kala Visvanathan; Amy Gross; Emily Maambo; Mamta Gupta; Elisabetta Kuhn; Rose Fanghong Li; Brigitte M Ronnett; Jeffrey D Seidman; Anna Yemelyanova; Ie-Ming Shih; Patricia A Shaw; Robert A Soslow; Robert J Kurman
Journal:  Int J Gynecol Pathol       Date:  2012-05       Impact factor: 2.762

4.  Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.

Authors:  Amy L Gross; Robert J Kurman; Russell Vang; Ie-Ming Shih; Kala Visvanathan
Journal:  J Oncol       Date:  2010-04-27       Impact factor: 4.375

5.  Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Authors:  Mark E Sherman; Marion Piedmonte; Phuong L Mai; Olga B Ioffe; Brigitte M Ronnett; Linda Van Le; Iouri Ivanov; Maria C Bell; Stephanie V Blank; Paul DiSilvestro; Chad A Hamilton; Krishnansu S Tewari; Katie Wakeley; Noah D Kauff; S Diane Yamada; Gustavo Rodriguez; Steven J Skates; David S Alberts; Joan L Walker; Lori Minasian; Karen Lu; Mark H Greene
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

Review 6.  Pathology of hereditary breast cancer.

Authors:  Petra van der Groep; Elsken van der Wall; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2011-02-19       Impact factor: 6.730

Review 7.  Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis.

Authors:  Jie Li; Oluwole Fadare; Li Xiang; Beihua Kong; Wenxin Zheng
Journal:  J Hematol Oncol       Date:  2012-03-09       Impact factor: 17.388

Review 8.  Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

Authors:  Nikos G Gavalas; Michalis Liontos; Sofia-Paraskevi Trachana; Tina Bagratuni; Calliope Arapinis; Christine Liacos; Meletios A Dimopoulos; Aristotle Bamias
Journal:  Int J Mol Sci       Date:  2013-07-30       Impact factor: 5.923

9.  Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families.

Authors:  Srdjan Novaković; Maša Milatović; Petra Cerkovnik; Vida Stegel; Mateja Krajc; Marko Hočevar; Janez Zgajnar; Aleš Vakselj
Journal:  Int J Oncol       Date:  2012-08-21       Impact factor: 5.650

10.  No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.

Authors:  B B J Hermsen; R I Olivier; R H M Verheijen; M van Beurden; J A de Hullu; L F Massuger; C W Burger; C T Brekelmans; M J Mourits; G H de Bock; K N Gaarenstroom; H H van Boven; T M Mooij; M A Rookus
Journal:  Br J Cancer       Date:  2007-04-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.